Jeffrey Eisele - 23 Jan 2024 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Signature
/s/ David Watson, attorney-in-fact for Jeffrey Eisele
Issuer symbol
APLS
Transactions as of
23 Jan 2024
Transactions value $
-$469,905
Form type
4
Filing time
24 Jan 2024, 16:03:55 UTC
Previous filing
23 Jan 2024
Next filing
31 Jan 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Sale -$469,904 -7,378 -11.21% $63.69 58,458 23 Jan 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This is a scheduled sale from an established 10b5-1 plan.